[theold]

Investors were underwhelmed by the study data as it reportedly failed to show superiority compared to a popular flu vaccine — Sanofi’s SNY Fluzone HD — and flu vaccines in pipeline including Novavax’s NVAX NanoFlu vaccine.

Shares of Moderna declined 5.6% on Dec 10, following the flu study data readout, reflecting investors’ disappointment. However, Moderna’s shares have gained 146.1% so far this year against the industry’s decrease of 22.7%.

https://sg.finance.yahoo.com/news/modern...03228.html